A patent lawsuit over-extraction methods involving two of the largest cannabis companies in the world sent ripples of worry through the industry earlier this year but attorneys and industry experts say it may be more bluster than anything else. In the case, filed late last year, Canadian giant Canopy Growth Corporation asserts ownership over a process used by GW Pharmaceuticals in the making of Epidiolex, the only cannabinoid-based medicine approved for use in the United States by the Food and Drug Administration. But while the lawsuit seems narrow in scope, a second patent, mentioned briefly in the case, could have ramifications for the entire extraction sector. The suit seeks to assert Patent No. 10,870,632, or “the 632 patent.” Canopy claims that GW Pharma uses its patented process to produce the cannabinoid-based, anti-epileptic Epidiolex, which the filing said made GW Pharma $366 million in net sales in the first nine months of 2020 alone.
Marijuana Venture, 02/15/2021 15:00:00